1
|
Desai S, Russel SM, Berk G, Kimple A. LGBTQIA+ Outness in Otolaryngology Residency Applications. J Surg Educ 2024; 81:620-624. [PMID: 38553371 DOI: 10.1016/j.jsurg.2024.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 01/28/2024] [Accepted: 02/03/2024] [Indexed: 04/26/2024]
Abstract
Lesbian, gay, bisexual, transgender, queer, intersex, and asexual/aromantic (LGBTQIA+) providers improve health outcomes of sexual and gender minority (SGM) patients, which demonstrates the importance of understanding the state of LGBTQIA+ representation at all levels of medical training. The U.S. does not systematically collect sexual orientation and gender identity (SOGI) data from applicants, trainees, and attending physicians, prompting us to wonder whether SGM representation in surgical fields, such as otolaryngology, is adequate. Personal statements submitted to an otolaryngology program from 2019 to 2021 were searched for LGBTQIA+ terms, and those containing LGBTQIA+ terms underwent full text review to determine whether applicants identified themselves as LGBTQIA+. Across these 2 application cycles, the sampled residency program received 928 applications. Only 2 applicants of 928 (0.2%) self-disclosed their LGBTQIA+ identities in their personal statements. These results signify a scarcity of SGM diversity in otolaryngology and warrant deeper exploration into factors preventing residency applicants from self-disclosure of LGBTQIA+ identities.
Collapse
Affiliation(s)
- Shivani Desai
- Department of Otolaryngology/Head and Neck Surgery, University of North Carolina - Chapel Hill, Chapel Hill, North Carolina
| | - Sarah M Russel
- Department of Otolaryngology/Head and Neck Surgery, University of North Carolina - Chapel Hill, Chapel Hill, North Carolina.
| | - Garrett Berk
- Department of Otolaryngology/Head and Neck Surgery, University of North Carolina - Chapel Hill, Chapel Hill, North Carolina
| | - Adam Kimple
- Department of Otolaryngology/Head and Neck Surgery, University of North Carolina - Chapel Hill, Chapel Hill, North Carolina
| |
Collapse
|
2
|
Bruce KE, Desai S, Reilly K, Keil A, Swanson M, Cobb B, Zahn K, McKenzie C, Coviello E, Mallampati D, Tully KP, Kolarczyk L, Maaske S, Quist-Nelson J. Use of Postpartum Hemorrhage Checklist during Vaginal Deliveries: A Quality Improvement Study. Am J Perinatol 2024. [PMID: 38452794 DOI: 10.1055/a-2282-8923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/09/2024]
Abstract
OBJECTIVE Postpartum hemorrhage (PPH) protocols improve patient safety and reduce utilization of blood products; however, few data exist on sustainability of PPH checklist use, how use affects care delivery, and variation of use among patient subgroups. This study aimed to (1) examine compliance with PPH checklist use during vaginal deliveries, (2) evaluate whether checklist use varied by patient and/or care team characteristics, and (3) evaluate whether checklist use was associated with increased use of recommended medications/interventions. STUDY DESIGN This was a quality improvement study performed from April 2021 through June 2023. A multidisciplinary team developed a revised PPH checklist and used quality improvement methodology to increase checklist use following vaginal birth. Data were collected from medical records and clinician survey. Control charts were generated to track checklist use and evaluate special cause variation. Chi-square tests and logistic regression were used to evaluate variation in medications/interventions and across subgroups. RESULTS During the study period, there were 342 cases of PPH at the time of vaginal birth. The checklist was used in 67% of PPH cases during the 20-month period after implementation in a setting where no checklist was previously being used. We found no statistically significant differences in checklist use by patient or health care team characteristics. Use of tranexamic acid, carboprost, and misoprostol were significantly associated with checklist use. CONCLUSION This study demonstrated successful implementation of a checklist protocol where no checklist was previously being used, with sustained use in an average of 67% of PPH cases over 20 months. Checklist use was consistent across subgroups and was associated with higher use of interventions shown to lower blood loss. KEY POINTS · Our study showed sustainability of PPH checklist use over a 20-month period.. · PPH checklist use was associated with increased use of interventions known to reduce blood loss.. · Checklist was used consistently across patient subgroups; may help address inequities in obstetric outcomes..
Collapse
Affiliation(s)
- Katharine E Bruce
- Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC
| | - Shivani Desai
- Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC
| | - Kelly Reilly
- Institute for Healthcare Quality Improvement, University of North Carolina Health, Chapel Hill, NC
| | - Arianna Keil
- Institute for Healthcare Quality Improvement, University of North Carolina Health, Chapel Hill, NC
| | - Michelle Swanson
- Department of Women's Services, University of North Carolina Health, Chapel Hill, NC
| | - Benjamin Cobb
- Department of Anesthesiology, University of North Carolina School of Medicine, Chapel Hill, NC
| | - Katelin Zahn
- Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC
| | - Christine McKenzie
- Department of Anesthesiology, University of North Carolina School of Medicine, Chapel Hill, NC
| | - Elizabeth Coviello
- Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC
| | - Divya Mallampati
- Department of Obstetrics and Gynecology, University of California San Francisco, San Francisco, CA
| | - Kristin P Tully
- Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC
| | - Lavinia Kolarczyk
- Department of Anesthesiology, University of North Carolina School of Medicine, Chapel Hill, NC
| | - Shannon Maaske
- Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC
| | - Johanna Quist-Nelson
- Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC
| |
Collapse
|
3
|
Abhale K, Veeranjaneyulu A, Desai S. A Snapshot of Biomarkers in Psoriasis. Curr Drug Discov Technol 2024; 21:CDDT-EPUB-139244. [PMID: 38500289 DOI: 10.2174/0115701638278470240312075112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Revised: 02/16/2024] [Accepted: 02/26/2024] [Indexed: 03/20/2024]
Abstract
A persistent long-standing, inflammatory skin condition that is brought on by a variety of factors is psoriasis. It is distinguished by itchy, scaly, reddish plaques, particularly on areas of the body that are frequently chafed, including the extensor sites of the limbs. Recent developments in molecular-targeted therapy that use biologics or small-molecule inhibitors can effectively cure even the worst psoriatic indications. The outstanding clinical outcomes of treatment help to clarify the disease's detrimental consequences on quality of life. Biomarkers that identify deep remission are essential for developing uniform treatment plans. Blood protein markers such as AMPs that are consistently quantifiable can be very helpful in routine clinical practice. The metabolic pathways involve biomarkers that can not only help diagnose psoriasis in a clinical setting but also indicate its severity based on the levels present in the body. Machine learning and AI have made a diagnosis of the expression of genes as biomarkers more accessible. In this article, biomarkers, as well as their key role in psoriasis, are discussed.
Collapse
Affiliation(s)
- Krushna Abhale
- Department of Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune
| | | | - Shivani Desai
- Clinical Research and Pharmacovigilance, Serum Institute of India Pvt. Ltd., Hadapsar, Pune
| |
Collapse
|
4
|
Abhale K, Veeranjaneyulu A, Desai S, Sanap A, Bhonde R. Effects of Mesenchymal Stem Cell-conditioned Media with Natural Immunomodulatory Agent Resveratrol on Type 1 Diabetes. Curr Drug Discov Technol 2024; 21:CDDT-EPUB-139054. [PMID: 38468534 DOI: 10.2174/0115701638276524240305054259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Revised: 01/18/2024] [Accepted: 01/29/2024] [Indexed: 03/13/2024]
Abstract
BACKGROUND Type 1 diabetes mellitus (T1DM) is a condition marked by elevated blood sugar levels and primarily recognized by the destruction of beta cells caused by an autoimmune attack, which is a significant characteristic of T1DM. Recent studies have demonstrated the regenerative potential of conditioned medium therapy. In light of this, the current research sought to assess the impact of Mesenchymal Stem Cell conditioned media (CM) and CM with resveratrol (CM+ Resveratrol) on the management of T1DM in Swiss albino mice. By leveraging and modifying existing conditioned medium therapy, this study aims to evaluate its effectiveness in treating T1DM. MATERIALS & METHODS Diabetes was induced in animals using the diabetes-inducing agent streptozotocin (STZ). The animals were then divided into five groups: Normal control, Disease Control, Resveratrol, Condition Media, and CM + Resveratrol. Treatments were given to the animals accordingly. The study period was 28 days. During this time, the animals were monitored for foodwater intake twice a week, blood glucose levels, and body weight. At the conclusion of the 28-day study period, biochemical estimations were performed for serum insulin levels, C-peptide levels, anti-inflammatory cytokines levels and pro-inflammatory cytokines levels. Additionally, histopathology of the pancreas was performed. RESULTS The test groups showed a significant decrease in blood glucose levels, an increase in Cpeptide levels, and a decrease in pro-inflammatory cytokine levels compared to the disease group. However, no statistically significant change within groups was observed in terms of serum insulin and anti-inflammatory cytokine levels. The improvement in diabetic symptoms, such as polyphagia, polydipsia, and weight loss, was observed in the treatment group, along with pancreatic regeneration, which indicated improved insulin secretion. CONCLUSION In the current investigation, we concluded that CM and CM+ Resveratrol, as natural immunomodulators, have the capacity to regenerate injured pancreatic beta cells and have antidiabetic action, together with immunomodulating impact. Nonetheless, future studies on this therapy appear to be promising.
Collapse
Affiliation(s)
- Krushna Abhale
- Department of Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune
| | | | - Shivani Desai
- Clinical Research and Pharmacovigilance, Serum Institute of India Pvt. Ltd., Hadapsar, Pune
| | - Avinash Sanap
- Regenerative Medicine Laboratory, Dr. D. Y. Patil Dental College and Hospital, Pimpri, Pune
| | - Ramesh Bhonde
- Regenerative Medicine Laboratory, Dr. D. Y. Patil Dental College and Hospital, Pimpri, Pune
| |
Collapse
|
5
|
Ben Suleiman A, Desai S, Tepperman A, Chvartszaid D, Malkhassian G, Habsha E, Barzilay I, Azarpazhooh A. The Outcomes of Endodontically Treated Teeth Restored with Custom-Made Cast Post-and-Core Restorations: A Retrospective Cohort Study. J Endod 2024; 50:316-328. [PMID: 38158119 DOI: 10.1016/j.joen.2023.12.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 12/18/2023] [Accepted: 12/19/2023] [Indexed: 01/03/2024]
Abstract
INTRODUCTION Custom-made cast post-and-core (CMCPC) restorations have long been used to restore structurally deficient endodontically treated teeth (ETT). However, the evidence regarding their impact on the outcomes of ETT is largely inconclusive. This study evaluated the long-term treatment outcome of ETT restored with CMCPC. METHODS This retrospective cohort study examined the dental records of patients that received CMCPC at a specialty private practice in Toronto, Canada between 1999 and 2021. The proportion of ETT with complete periapical healing and those that survived were estimated, and prognostic factors were investigated using multiple logistic and Cox regression analyses respectively (P < .05). RESULTS A total of 500 and 1000 teeth met periapical healing and survival criteria, respectively. The periapical healing rate was 88.8% and was associated with the presence of baseline periapical radiolucency [odds ratio = 0.1; 95% confidence interval (CI), 0.05-0.2; P < .001]. The survival after a median follow-up time of 52.9 months (interquartile range: 26.5-99.4) was 90.1% and was associated with <75% of root length in bone [hazard ratio (HR) = 2.6; 95% CI, 1.0-6.6; P = .033], type and quality of final restoration (HR = 2.09; 95% CI, 1.1-3.9; P = .020; HR = 2.3; 95% CI, 1.2-4.5; P = .008, respectively), and the presence of periapical radiolucency at the latest recall (HR = 3.2; 95% CI, 1.7-6.3; P < .001). CONCLUSIONS The outcome of ETT restored with CMCPC was favorable. CMCPC may be regarded as a viable restorative option for structurally deficient ETT.
Collapse
Affiliation(s)
| | - Shivani Desai
- Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada; Centre for Advanced Dental Research and Care, Mount Sinai Hospital, Toronto, Ontario, Canada
| | - Adam Tepperman
- Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada
| | - David Chvartszaid
- Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada; Centre for Advanced Dental Research and Care, Mount Sinai Hospital, Toronto, Ontario, Canada; The Alpha Omega Dental Centre, Baycrest Hospital, Toronto, Ontario, Canada
| | - Gevik Malkhassian
- Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada
| | - Effrat Habsha
- Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada; Centre for Advanced Dental Research and Care, Mount Sinai Hospital, Toronto, Ontario, Canada; Prosthodontic Associates Centre for Excellence, Toronto, Ontario, Canada
| | - Izchak Barzilay
- Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada; Centre for Advanced Dental Research and Care, Mount Sinai Hospital, Toronto, Ontario, Canada; Prosthodontic Associates Centre for Excellence, Toronto, Ontario, Canada
| | - Amir Azarpazhooh
- Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada; Centre for Advanced Dental Research and Care, Mount Sinai Hospital, Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
| |
Collapse
|
6
|
Sharma H, Parekh S, Pujari P, Shewale S, Desai S, Kawade A, Lalwani S, Ravi MD, Kamath V, Mahopatra J, Kulkarni G, Tayade D, Ramanan PV, Uttam KG, Rawal L, Gawande A, Kumar NR, Tiple N, Vagha J, Thakkar P, Khandgave P, Deshmukh BJ, Agarwal A, Dogar V, Gautam M, Jaganathan KS, Kumar R, Sharma I, Gairola S. A phase III randomized-controlled study of safety and immunogenicity of DTwP-HepB-IPV-Hib vaccine (HEXASIIL ®) in infants. NPJ Vaccines 2024; 9:41. [PMID: 38383584 PMCID: PMC10881502 DOI: 10.1038/s41541-024-00828-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Accepted: 02/08/2024] [Indexed: 02/23/2024] Open
Abstract
A fully liquid hexavalent containing Diphtheria (D), Tetanus (T) toxoids, whole cell Pertussis (wP), Hepatitis B (Hep B), type 1, 2, 3 of inactivated poliovirus (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (DTwP-HepB-IPV-Hib vaccine, HEXASIIL®) was tested for lot-to-lot consistency and non-inferiority against licensed DTwP-HepB-Hib + IPV in an open label, randomized Phase II/III study. In Phase III part, healthy infants received DTwP-HepB-IPV-Hib or DTwP-HepB-Hib + IPV vaccines at 6, 10 and 14 weeks of age. Blood samples were collected prior to the first dose and 28 days, post dose 3. Non inferiority versus DTwP-HepB-Hib + IPV was demonstrated with 95% CIs for the treatment difference for seroprotection/seroconversion rates. For DTwP-HepB-IPV-Hib lots, limits of 95% CI for post-vaccination geometric mean concentration ratios were within equivalence limits (0.5 and 2). Vaccine was well-tolerated and no safety concerns observed.Clinical Trial Registration - CTRI/2019/11/022052.
Collapse
Affiliation(s)
- Hitt Sharma
- Department of Clinical Research and Pharmacovigilance, Serum Institute of India Pvt. Ltd., Pune, India.
| | - Sameer Parekh
- Department of Clinical Research and Pharmacovigilance, Serum Institute of India Pvt. Ltd., Pune, India
| | - Pramod Pujari
- Department of Clinical Research and Pharmacovigilance, Serum Institute of India Pvt. Ltd., Pune, India
| | - Sunil Shewale
- Department of Clinical Research and Pharmacovigilance, Serum Institute of India Pvt. Ltd., Pune, India
| | - Shivani Desai
- Department of Clinical Research and Pharmacovigilance, Serum Institute of India Pvt. Ltd., Pune, India
| | - Anand Kawade
- Department of Pediatrics, KEM Hospital Research Centre, Vadu, Pune, India
| | - Sanjay Lalwani
- Department of Pediatrics, Bharati Vidyapeeth (Deemed to be University) Medical College & Hospital, Pune, India
| | - M D Ravi
- Department of Pediatrics, JSS Hospital, Mysuru, India
| | - Veena Kamath
- Department of Community Medicine, Kasturba Medical College, Manipal Academy of Higher Education (MAHE), Manipal, India
| | - Jagannath Mahopatra
- Department of Pediatrics, Hamdard Institute of Medical Science and Research, New Delhi, India
| | - Ganesh Kulkarni
- Department of Pediatrics, Sanjeevani Children's Hospital, Aurangabad, India
| | - Deepak Tayade
- Department of Pediatrics, Mahatma Gandhi Mission's Medical College and Hospital, Aurangabad, India
| | | | | | - Lalit Rawal
- Department of Pediatrics, Grant Medical Foundation Ruby Hall Clinic, Pune, India
| | - Avinash Gawande
- Department of Pediatrics, Government Medical College and Hospital, Nagpur, India
| | - N Ravi Kumar
- Department of Pediatrics, Niloufer Hospital, Hyderabad, India
| | - Nishikant Tiple
- Department of Pediatrics, Government Medical College, Chandrapur, India
| | - Jayant Vagha
- Department of Pediatrics, Acharya Vinoba Bhave Rural Hospital, Wardha, India
| | | | | | | | - Anurag Agarwal
- Department of Pediatrics, Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, India
| | - Vikas Dogar
- Department of Quality Control, Serum Institute of India Pvt. Ltd, Pune, India
| | - Manish Gautam
- Department of Quality Control, Serum Institute of India Pvt. Ltd, Pune, India
| | - K S Jaganathan
- Production Department, Serum Institute of India Pvt. Ltd, Pune, India
| | - Rakesh Kumar
- Production Department, Serum Institute of India Pvt. Ltd, Pune, India
| | - Inderjit Sharma
- Production Department, Serum Institute of India Pvt. Ltd, Pune, India
| | - Sunil Gairola
- Department of Quality Control, Serum Institute of India Pvt. Ltd, Pune, India
| |
Collapse
|
7
|
Gaviola GC, Desai S. Immunization requirements in medical school accreditation standards. Vaccine 2024; 42:753-756. [PMID: 37127525 DOI: 10.1016/j.vaccine.2023.04.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Revised: 04/05/2023] [Accepted: 04/06/2023] [Indexed: 05/03/2023]
Abstract
Healthcare workers (HCW) are at risk of contracting vaccine-preventable diseases and spreading these infections to their patients. Vaccination against preventable diseases prior to clinical training can mitigate this risk. Accreditation guidance can be used as an opportunity to enforce desirable norms and standards. Standards from 144 national accreditation organizations spanning 123 member states listed in the Directory of Organizations that Recognize/Accredit Medical Schools by the Foundation for Advancement of International Medical Education and Research were reviewed and summarized. Findings were further stratified by World Bank income group and WHO region. While higher-income countries were more likely to have accreditation guidelines available than lower- or middle-income countries, few national medical school accreditation bodies specifically request immunization status of trainees as a standard. Further, almost none mention specific antigens for which immunity should be assessed. These findings should be used by medical school and other health professional training accreditation bodies to inform future policy direction to protect trainees as future HCW.
Collapse
Affiliation(s)
- G C Gaviola
- Division of Occupational Medicine, Cambridge Health Alliance/Harvard Medical School, Cambridge, MA, United States
| | - S Desai
- Immunization, Vaccines and Biologicals, World Health Organization, Switzerland.
| |
Collapse
|
8
|
Desai S, Desai T. Hypoechogenic corpus callosal area in fetus: elucidating true microarchitecture with fetal MRI fiber tractography. Ultrasound Obstet Gynecol 2024; 63:278-279. [PMID: 37579067 DOI: 10.1002/uog.27455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/28/2023] [Revised: 07/27/2023] [Accepted: 08/04/2023] [Indexed: 08/16/2023]
Affiliation(s)
- S Desai
- Fetal Neuroimaging Clinic, Department of Fetal Medicine, Infocus Diagnostics, Ahmedabad, Gujarat, India
| | - T Desai
- Department of Radiology, Infocus Diagnostics, Ahmedabad, Gujarat, India
| |
Collapse
|
9
|
Demopoulos C, Jesson X, Gerdes MR, Jurigova BG, Hinkley LB, Ranasinghe KG, Desai S, Honma S, Mizuiri D, Findlay A, Nagarajan SS, Marco EJ. Global MEG Resting State Functional Connectivity in Children with Autism and Sensory Processing Dysfunction. bioRxiv 2024:2024.01.26.577499. [PMID: 38352614 PMCID: PMC10862722 DOI: 10.1101/2024.01.26.577499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/20/2024]
Abstract
Sensory processing dysfunction not only affects most individuals with autism spectrum disorder (ASD), but at least 5% of children without ASD also experience dysfunctional sensory processing. Our understanding of the relationship between sensory dysfunction and resting state brain activity is still emerging. This study compared long-range resting state functional connectivity of neural oscillatory behavior in children aged 8-12 years with autism spectrum disorder (ASD; N=18), those with sensory processing dysfunction (SPD; N=18) who do not meet ASD criteria, and typically developing control participants (TDC; N=24) using magnetoencephalography (MEG). Functional connectivity analyses were performed in the alpha and beta frequency bands, which are known to be implicated in sensory information processing. Group differences in functional connectivity and associations between sensory abilities and functional connectivity were examined. Distinct patterns of functional connectivity differences between ASD and SPD groups were found only in the beta band, but not in the alpha band. In both alpha and beta bands, ASD and SPD cohorts differed from the TDC cohort. Somatosensory cortical beta-band functional connectivity was associated with tactile processing abilities, while higher-order auditory cortical alpha-band functional connectivity was associated with auditory processing abilities. These findings demonstrate distinct long-range neural synchrony alterations in SPD and ASD that are associated with sensory processing abilities. Neural synchrony measures could serve as potential sensitive biomarkers for ASD and SPD.
Collapse
Affiliation(s)
- Carly Demopoulos
- Department of Psychiatry, University of California San Francisco, 675 18 Street, San Francisco, CA 94107
- Department of Radiology & Biomedical Imaging, University of California-San Francisco, 513 Parnassus Avenue, S362, San Francisco, CA 94143
| | - Xuan Jesson
- Department of Psychology, Palo Alto University, 1791 Arastradero Road, Palo Alto, CA 94304
| | - Molly Rae Gerdes
- Cortica Healthcare, Department of Neurodevelopmental Medicine, 4000 Civic Center Drive, San Rafael, CA 94903
| | - Barbora G. Jurigova
- Cortica Healthcare, Department of Neurodevelopmental Medicine, 4000 Civic Center Drive, San Rafael, CA 94903
| | - Leighton B. Hinkley
- Department of Radiology & Biomedical Imaging, University of California-San Francisco, 513 Parnassus Avenue, S362, San Francisco, CA 94143
| | - Kamalini G. Ranasinghe
- University of California-San Francisco, Department of Neurology, 675 Nelson Rising Lane, San Francisco, CA 94143
| | - Shivani Desai
- University of California-San Francisco, Department of Neurology, 675 Nelson Rising Lane, San Francisco, CA 94143
| | - Susanne Honma
- Department of Radiology & Biomedical Imaging, University of California-San Francisco, 513 Parnassus Avenue, S362, San Francisco, CA 94143
| | - Danielle Mizuiri
- Department of Radiology & Biomedical Imaging, University of California-San Francisco, 513 Parnassus Avenue, S362, San Francisco, CA 94143
| | - Anne Findlay
- Department of Radiology & Biomedical Imaging, University of California-San Francisco, 513 Parnassus Avenue, S362, San Francisco, CA 94143
| | - Srikantan S. Nagarajan
- Department of Radiology & Biomedical Imaging, University of California-San Francisco, 513 Parnassus Avenue, S362, San Francisco, CA 94143
| | - Elysa J. Marco
- Cortica Healthcare, Department of Neurodevelopmental Medicine, 4000 Civic Center Drive, San Rafael, CA 94903
| |
Collapse
|
10
|
Bouzidi MS, Dossani ZY, Di Benedetto C, Raymond KA, Desai S, Chavez LR, Betancur P, Pillai SK. High-resolution Inference of Multiplexed Anti-HIV Gene Editing using Single-Cell Targeted DNA Sequencing. bioRxiv 2024:2024.01.24.576921. [PMID: 38328062 PMCID: PMC10849705 DOI: 10.1101/2024.01.24.576921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/09/2024]
Abstract
Gene therapy-based HIV cure strategies typically aim to excise the HIV provirus directly, or target host dependency factors (HDFs) that support viral persistence. Cure approaches will likely require simultaneous co-targeting of multiple sites within the HIV genome to prevent evolution of resistance, and/or co-targeting of multiple HDFs to fully render host cells refractory to HIV infection. Bulk cell-based methods do not enable inference of co-editing within individual viral or target cell genomes, and do not discriminate between monoallelic and biallelic gene disruption. Here, we describe a targeted single-cell DNA sequencing (scDNA-seq) platform characterizing the near full-length HIV genome and 50 established HDF genes, designed to evaluate anti-HIV gene therapy strategies. We implemented the platform to investigate the capacity of multiplexed CRISPR-Cas9 ribonucleoprotein complexes (Cas9-RNPs) to simultaneously 1) inactivate the HIV provirus, and 2) knockout the CCR5 and CXCR4 HDF (entry co-receptor) genes in microglia and primary monocyte-derived macrophages (MDMs). Our scDNA-seq pipeline revealed that antiviral gene editing is rarely observed at multiple loci (or both alleles of a locus) within an individual cell, and editing probabilities across sites are linked. Our results demonstrate that single-cell sequencing is critical to evaluate the true efficacy and therapeutic potential of HIV gene therapy.
Collapse
Affiliation(s)
- Mohamed S. Bouzidi
- Vitalant Research Institute, San Francisco, CA, USA
- Department of Laboratory Medicine, University of California, San Francisco, CA, USA
| | - Zain Y. Dossani
- Vitalant Research Institute, San Francisco, CA, USA
- Department of Laboratory Medicine, University of California, San Francisco, CA, USA
| | | | - Kyle A. Raymond
- Vitalant Research Institute, San Francisco, CA, USA
- Department of Virology, Institut Pasteur, Université de Paris, CNRS UMR3569, Paris, France
| | | | - Leonard R. Chavez
- Vitalant Research Institute, San Francisco, CA, USA
- Rewrite Therapeutics, Berkeley, CA, USA
| | - Paola Betancur
- Department of Radiation Oncology, University of California, San Francisco, CA, USA
| | - Satish K. Pillai
- Vitalant Research Institute, San Francisco, CA, USA
- Department of Laboratory Medicine, University of California, San Francisco, CA, USA
| |
Collapse
|
11
|
Surani V, Chatterjee S, Jaggi S, Banka N, Desai S, Rodge G. Curious Case of a Giant Retroperitoneal Cyst. Cureus 2024; 16:e51758. [PMID: 38318574 PMCID: PMC10843365 DOI: 10.7759/cureus.51758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/06/2024] [Indexed: 02/07/2024] Open
Abstract
Adrenal cysts are uncommon fluid-filled masses that develop in the adrenal gland. Typically, they are non-functional, asymptomatic, and smaller than 10 cm in diameter when incidentally detected. However, the presence of giant adrenal cysts, exceeding 10 cm in diameter, creates a diagnostic challenge due to the difficulty in determining their origin. Surgical intervention is advised when the cyst surpasses 10 cm in diameter, produces symptoms, causes endocrine abnormalities, exhibits intracystic bleeding, or raises suspicion of malignancy. The preferred treatment approach involves adrenalectomy, performed either through open surgery or laparoscopy. In cases where the diagnosis is unequivocal, ultrasound-guided percutaneous drainage serves as an alternative. Here, we present an exceptional case of a massive retroperitoneal mass caused by a rare giant adrenal cyst.
Collapse
Affiliation(s)
- Viral Surani
- Gastroenterology and Hepatology, Bombay Hospital and Medical Research Center, Mumbai, IND
| | | | - Sunila Jaggi
- Radiology, Bombay Hospital and Medical Research Center, Mumbai, IND
| | - Niranjan Banka
- Gastroenterology and Hepatology, Bombay Hospital and Medical Research Center, Mumbai, IND
| | - Shivani Desai
- General Surgery, Bombay Hospital Institute of Medical Sciences, Mumbai, IND
| | - Gajanan Rodge
- Gastroenterology and Hepatology, Bombay Hospital and Medical Research Center, Mumbai, IND
| |
Collapse
|
12
|
Kucirka LM, Desai S, LeVarge B, Conklin JL, Leong ME, Quist-Nelson J. Unilateral Absent Pulmonary Artery in Pregnancy: A Case Report and Systematic Literature Review. Am J Perinatol 2023. [PMID: 37995742 DOI: 10.1055/a-2217-0241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2023]
Abstract
OBJECTIVE Unilateral absence of a pulmonary artery (UAPA) is a rare congenital malformation associated with hemoptysis, pulmonary hypertension, and infection. Little is known about the impact on pregnancy outcomes. We sought to synthesize the existing literature on pregnancy outcomes in patients with maternal UAPA. STUDY DESIGN We report a case of maternal UAPA and performed a systematic review of the existing literature. Articles in English reporting pregnancy outcomes among women with unilateral absence or hypoplasia of the pulmonary artery were included. Articles were reviewed at the abstract level and, if eligible, at the full-text level by two independent reviewers with disagreements adjudicated by a third reviewer. Data were abstracted by two independent reviewers. Outcomes of interest were mode of delivery, gestational age at delivery, intensive care admission, maternal death, and length of stay. Summary statistics for each outcome are presented. RESULTS We identified 14 studies, including the presented case, reporting outcomes in 22 pregnancies impacted by maternal UAPA. Median age at diagnosis was 21 years. Concurrent cardiac comorbidities were reported in 6/13 (46.2%) with pulmonary hypertension in 5/20 (25%) of cases where this information was reported. We observed high rates of preterm birth (4/12, 33.3%), cesarean delivery (10/15, 66.7%), and operative vaginal delivery (2/5, 40.0%). There was one maternal death occurring in the immediate postpartum period for a mortality rate of 4.5%. CONCLUSION Our study provides a comprehensive review of existing literature on maternal UAPA. Our findings suggest increased rates of adverse outcomes and underscore the importance of early diagnosis, identification of pulmonary hypertension, and multidisciplinary care. KEY POINTS · There may be increased adverse outcomes in maternal UAPA.. · Concurrent cardiac abnormalities are common in maternal UAPA.. · Early diagnosis, identification of pulmonary hypertension, and multidisciplinary care are important..
Collapse
Affiliation(s)
- Lauren M Kucirka
- Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Shivani Desai
- University of North Carolina School of Medicine, Chapel Hill, North Carolina
| | - Barbara LeVarge
- Division of Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Jamie L Conklin
- Health Sciences Library, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - M Elisabeth Leong
- Division of Pediatric Cardiology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Johanna Quist-Nelson
- Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| |
Collapse
|
13
|
Desai S, Carbonell C, Hoffman K, Hammond B, Crosier C, Blackhurst D, Carbonell AM, Love MW, Cobb WS, Warren JA. Impact of methocarbamol on opioid use after ventral incisional hernia repair. Am J Surg 2023; 226:858-863. [PMID: 37481407 DOI: 10.1016/j.amjsurg.2023.07.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Revised: 06/12/2023] [Accepted: 07/05/2023] [Indexed: 07/24/2023]
Abstract
BACKGROUND Alternatives to opioid analgesia are needed to reduce the risk of abuse, misuse, and diversion. Musculoskeletal pain is a significant contributor to postoperative pain after ventral hernia repair (VHR). We report the impact of methocarbamol on opioid prescribing after VHR. METHODS Review of all robotic and open VHR, Jan 2020-July 2022. Data was collected in the Abdominal Core Health Quality Collaborative (ACHQC) with additional chart review to assess for opioid refills. A 2:1 propensity score match was performed comparing opioid prescribing in patients prescribed vs not prescribed methocarbamol. RESULTS 101 patients received methocarbamol compared with 202 without. Similar number of patients received an opioid prescription (87.1 vs 86.6%; p = 0.904). Study patients received significantly lower MME prescription at discharge (60 v 75; p = 0.021) with no difference in refills (12.5 vs 16.6%; p = 0.386). CONCLUSION Addition of methocarbamol to a multimodal analgesic regimen after VHR facilitates reduction in prescribed opioid with no increase in refills.
Collapse
Affiliation(s)
| | - Cecilia Carbonell
- Prisma Health Department of Surgery, Summer Program for Undergraduate Research in Surgery, USA
| | | | - Brooke Hammond
- Prisma Health Department of Surgery, Summer Program for Undergraduate Research in Surgery, USA
| | | | | | - Alfredo M Carbonell
- Prisma Health Department of Surgery, USA; University of South Carolina School of Medicine Greenville, USA
| | | | - William S Cobb
- Prisma Health Department of Surgery, USA; University of South Carolina School of Medicine Greenville, USA
| | - Jeremy A Warren
- Prisma Health Department of Surgery, USA; University of South Carolina School of Medicine Greenville, USA.
| |
Collapse
|
14
|
Crosier C, Hammond B, Carbonell C, Hoffman K, Desai S, Blackhurst D, Carbonell AM, Love MW, Cobb WS, Warren JA. Impact of methocarbamol on opioid use after primary ventral and inguinal hernia repair. Am J Surg 2023; 226:813-816. [PMID: 37385858 DOI: 10.1016/j.amjsurg.2023.06.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Revised: 06/13/2023] [Accepted: 06/20/2023] [Indexed: 07/01/2023]
Abstract
BACKGROUND Multimodal analgesia is now a mainstay of perioperative care. Our aim is to assess the impact of adding methocarbamol on opioid use for patients undergoing primary ventral (umbilical and epigastric) hernia repair (PVHR) and inguinal hernia repair (IHR). METHODS Retrospective review of patients undergoing PVHR and IHR who received methocarbamol, propensity score matched in a 2:1 fashion to patients not receiving methocarbamol. RESULTS Fifty-two PVHR patients receiving methocarbamol were matched to 104 control patients. Study patients were prescribed fewer opioids (55.8 vs 90.4%; p < 0.001) and received lower MME (20 vs 50; p < 0.001), with no difference in refills or rescue opioids. For IHR, study patients received fewer prescriptions (67.3 vs 87.5%; p < 0.001) and received lower MME (25 vs 40; p < 0.001), with no difference in rescue opioid (5.9 vs 0%; p = 0.374). CONCLUSIONS Methocarbamol significantly reduced opioid prescribing in patients undergoing PVHR and IHR without increasing the risk of refill or rescue opioid.
Collapse
Affiliation(s)
| | - Brooke Hammond
- Prisma Health Department of Surgery, Summer Program for Undergraduate Research in Surgery, United States
| | - Cecilia Carbonell
- Prisma Health Department of Surgery, Summer Program for Undergraduate Research in Surgery, United States
| | | | | | | | - Alfredo M Carbonell
- Prisma Health Department of Surgery, United States; University of South Carolina School of Medicine Greenville, United States
| | - Michael W Love
- Prisma Health Department of Surgery, United States; University of South Carolina School of Medicine Greenville, United States
| | - William S Cobb
- Prisma Health Department of Surgery, United States; University of South Carolina School of Medicine Greenville, United States
| | - Jeremy A Warren
- Prisma Health Department of Surgery, United States; University of South Carolina School of Medicine Greenville, United States.
| |
Collapse
|
15
|
Sharma H, Parekh S, Pujari P, Shewale S, Desai S, Bhatla N, Joshi S, Pimple S, Kawade A, Balasubramani L, Thomas A, Suri V, Lalwani S, Uday R, Kamath V, Mandal R, Rajeswar A, Peedicayil A, Poli UR, Banerjee D, Sankaranarayanan R, Basu P, Muwonge R, Gairola S, Dogar V, Rao H, Shaligram U. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial. Lancet Oncol 2023; 24:1321-1333. [PMID: 37949086 DOI: 10.1016/s1470-2045(23)00480-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Revised: 09/21/2023] [Accepted: 09/21/2023] [Indexed: 11/12/2023]
Abstract
BACKGROUND To meet global cervical cancer elimination efforts, a wider range of affordable and accessible vaccines against human papillomavirus (HPV) are needed. We aimed to evaluate the immunogenicity and safety of a quadrivalent HPV vaccine (targeting HPV types 6, 11, 16, and 18), developed and manufactured by the Serum Institute of India (SIIPL). Here we report outcomes in the 9-14 years cohort. METHODS This randomised, active-controlled, phase 2/3 trial was conducted at 12 tertiary care hospitals across India. Healthy participants aged 9-14 years or 15-26 years with no history of HPV vaccination were eligible for enrolment. Female participants were randomly assigned (1:1) with an interactive web response system, by use of a central computer-generated schedule and block randomisation (block sizes of 2, 4, 6, and 8), to receive the SIIPL quadrivalent HPV vaccine (Cervavac; SIIPL, Pune, India) or the comparator quadrivalent HPV vaccine (Gardasil; Merck Sharp & Dohme, Harleem, the Netherlands). Participants, investigators, laboratory technicians, and sponsors were masked to treatment allocation of female participants. Male participants were given the SIIPL quadrivalent HPV vaccine in an open-label manner. Study vaccines were administered intramuscularly with a two-dose schedule (at day 0 and 6 months) in the cohort aged 9-14 years, and with a three-dose schedule (at day 0, month 2, and month 6) in the cohort aged 15-26-years. Immunogenicity was assessed 30 days after the last dose by use of multiplexed ELISA. The primary outcome was the non-inferiority of immune response in terms of the geometric mean titre (GMT) of antibodies against HPV types 6, 11, 16, and 18 generated by the SIIPL quadrivalent HPV vaccine in girls and boys (aged 9-14 years) compared with the GMT generated by the comparator quadrivalent HPV vaccine in women aged 15-26 years at month 7 in the modified per-protocol population (ie, all participants who received all doses of study vaccines per assigned treatment group and had both day 0 and 1-month immunogenicity measurements after the last dose following protocol-defined window periods with no major protocol deviations). Non-inferiority was established if the lower bound of the 98·75% CI of the GMT ratio was 0·67 or higher. The co-primary outcome of occurrence of solicited adverse events (within 7 days of each dose) and unsolicited adverse events (up to 30 days after the last dose) was assessed in all participants who were enrolled and received at least one dose of study vaccine. The trial is registered with the Clinical Trials Registry - India (CTRI/2018/06/014601), and long-term follow-up is ongoing. FINDINGS Between Sept 20, 2018, and Feb 9, 2021, 2341 individuals were screened, of whom 2307 eligible individuals were enrolled and vaccinated: 1107 (738 girls and 369 boys) in the cohort aged 9-14 years and 1200 (819 women and 381 men) in the cohort aged 15-26 years. No race or ethnicity data were collected. 350 girls and 349 boys in the SIIPL quadrivalent HPV vaccine group and 338 women in the comparator vaccine group were included in the modified per-protocol population for the primary endpoint analysis. The median follow-up for the analyses was 221 days (IQR 215-231) for girls and 222 days (217-230) for boys in the SIIPL quadrivalent HPV vaccine group, 223 days (216-232) for girls in the comparator vaccine group, and 222 days (216-230) for women in the comparator vaccine group. GMT ratios were non-inferior in girls and boys receiving the SIIPL quadrivalent HPV vaccine compared with women receiving the comparator vaccine: GMT ratios for girls were 1·97 (98·75% CI 1·67-2·32) for HPV type 6, 1·63 (1·38-1·91) for HPV type 11, 1·90 (1·60-2·25) for HPV type 16, and 2·16 (1·79-2·61) for HPV type 18. For boys the GMT ratios were 1·86 (1·57-2·21) for HPV type 6, 1·46 (1·23-1·73) for HPV type 11, 1·62 (1·36-1·94) for HPV type 16, and 1·80 (1·48-2·18) for HPV type 18. The safety population comprised all 1107 participants (369 girls and 369 boys in the SIIPL quadrivalent HPV vaccine group, and 369 girls in the comparator group). Solicited adverse events occurred in 176 (48%) of 369 girls and 124 (34%) of 369 boys in the SIIPL vaccine group and 179 (49%) of 369 girls in the comparator vaccine group. No grade 3-4 solicited adverse events occurred within 7 days of each dose. Unsolicited adverse events occurred in 143 (39%) girls and 147 (40%) boys in the SIIPL vaccine group, and 143 (39%) girls in the comparator vaccine group. The most common grade 3 unsolicited adverse event was dengue fever, in one (<1%) girl in the SIIPL vaccine group and three (1%) girls in the comparator group. There were no grade 4 or 5 adverse events. Serious adverse events occurred in three (1%) girls and three (1%) boys in the SIIPL vaccine group, and five (1%) girls in the comparator vaccine group. No vaccine-related serious adverse events were reported. There were no treatment-related deaths. INTERPRETATION We observed a non-inferior immune response with the SIIPL quadrivalent HPV vaccine in girls and boys aged 9-14 years and an acceptable safety profile compared with the comparator vaccine. These findings support extrapolation of efficacy from the comparator vaccine to the SIIPL quadrivalent HPV vaccine in the younger population. The availability of the SIIPL quadrivalent HPV vaccine could help meet the global demand for HPV vaccines, and boost coverage for both girls and boys globally. FUNDING Biotechnology Industry Research Assistance Council, Department of Biotechnology (DBT), Government of India, and Serum Institute of India.
Collapse
Affiliation(s)
| | | | | | | | | | - Neerja Bhatla
- All India Institute of Medical Sciences, New Delhi, India
| | | | - Sharmila Pimple
- Tata Memorial Hospital & Cancer Research Institute, Mumbai, India
| | | | | | | | - Vanita Suri
- Postgraduate Institute of Medical Education & Research, Chandigarh, India
| | - Sanjay Lalwani
- Bharati Vidyapeeth Medical College & Hospital, Pune, India
| | - Rajini Uday
- M S Ramaiah Medical College & Hospital, Bangalore, India
| | - Veena Kamath
- Kasturba Medical College and TMA Pai Hospital, Manipal, India
| | | | - A Rajeswar
- MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad, India
| | | | - Usha Rani Poli
- MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad, India
| | | | | | - Partha Basu
- International Agency for Research on Cancer, World Health Organization, Early Detection, Prevention and Infections Branch, Lyon, France
| | - Richard Muwonge
- International Agency for Research on Cancer, World Health Organization, Early Detection, Prevention and Infections Branch, Lyon, France
| | | | | | | | | |
Collapse
|
16
|
Aydin I, May M, Pisano F, Mpofu-Maetzig N, Grode L, Parekh S, Pujari P, Shewale S, Desai S, Sharma H, Rao H, Gautam M, Gairola S, Shaligram U. Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany. Vaccine 2023:S0264-410X(23)01157-X. [PMID: 37827966 DOI: 10.1016/j.vaccine.2023.09.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 09/27/2023] [Accepted: 09/28/2023] [Indexed: 10/14/2023]
Abstract
BACKGROUND This study assessed the safety and immunogenicity of a new booster vaccine against tetanus, diphtheria, and pertussis manufactured by Serum Institute of India Pvt. Ltd (SIIPL Tdap). METHODS The Phase II/III trial was randomized (2:1), observer blinded and active controlled. Healthy subjects aged 4-65 years received a single dose of either SIIPL Tdap or comparator Tdap vaccine (Boostrix®, GlaxoSmithKline, Belgium), and were followed-up for 30 days. Blood samples for safety and immunogenicity assessments were collected pre-vaccination and on day 30 post-vaccination. The study assessed safety and reactogenicity of SIIPL Tdap compared to the comparator Tdap as well as the co-primary immunogenicity outcomes: (i) seroprotection rates against diphtheria toxoid (DT) and tetanus toxoid (TT) and (ii) the booster response rates against pertussis toxoid (PT), filamentous hemagglutinin (FHA) and pertactin (PRN) 30 days post-vaccination in all study subjects. A margin of -10 % was used for non-inferiority testing. Secondary outcomes included the booster response rates against DT and TT, seropositivity rates against pertussis antigens, and antibody geometric mean concentrations (GMCs) for all vaccine components. RESULTS At Day 30 post-vaccination, SIIPL Tdap was assessed as non-inferior to the comparator Tdap in terms of: i) seroprotection rates against DT (94.4 % vs. 94.9 %) and TT (99.9 % vs. 100 %) and ii) pertussis booster response rates (93.8 % vs. 88.4 % anti-PT, 89.7 % vs. 90.9 % anti-FHA and 86.3 % vs. 84.4 % anti-PRN), for SIIPL Tdap versus comparator Tdap, respectively. GMCs for anti-PT and anti-PRN were higher in subjects vaccinated with SIIPL Tdap compared to comparator Tdap. All other secondary outcomes were comparable. The overall frequency of local and systemic solicited AEs was comparable; no treatment related SAEs were reported. CONCLUSIONS Booster vaccination with SIIPL Tdap was non-inferior to comparator Tdap with respect to the immunogenicity of the vaccine components and was equally well tolerated. EudraCT number: 2019-002706-46.
Collapse
Affiliation(s)
- Inci Aydin
- Serum Life Science Europe GmbH, Hannover, Germany.
| | - Marcus May
- Serum Life Science Europe GmbH, Hannover, Germany
| | - Fabio Pisano
- Serum Life Science Europe GmbH, Hannover, Germany.
| | | | | | - Sameer Parekh
- Serum Institute of India Private Limited, Pune, India
| | - Pramod Pujari
- Serum Institute of India Private Limited, Pune, India
| | - Sunil Shewale
- Serum Institute of India Private Limited, Pune, India
| | - Shivani Desai
- Serum Institute of India Private Limited, Pune, India
| | - Hitt Sharma
- Serum Institute of India Private Limited, Pune, India
| | - Harish Rao
- Serum Institute of India Private Limited, Pune, India
| | - Manish Gautam
- Serum Institute of India Private Limited, Pune, India
| | - Sunil Gairola
- Serum Institute of India Private Limited, Pune, India
| | | |
Collapse
|
17
|
Desai S, Carberry BJ, Anseth KS, Schultz KM. Characterizing rheological properties and microstructure of thioester networks during degradation. Soft Matter 2023; 19:7429-7442. [PMID: 37743747 PMCID: PMC10714141 DOI: 10.1039/d3sm00864a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/26/2023]
Abstract
Covalent adaptable networks are designed for applications including cell and drug delivery and tissue regeneration. These applications require network degradation at physiological conditions and on a physiological timescale with microstructures that can: (1) support, protect and deliver encapsulated cells or molecules and (2) provide structure to surrounding tissue. Due to this, the evolving microstructure and rheological properties during scaffold degradation must be characterized. In this work, we characterize degradation of covalent adaptable poly(ethylene glycol) (PEG)-thioester networks with different amounts of excess thiol. Networks are formed between PEG-thiol and PEG-thioester norbornene using photopolymerization. These networks are adaptable because of a thioester exchange reaction that takes place in the presence of excess thiol. We measure degradation of PEG-thioester networks with L-cysteine using multiple particle tracking microrheology (MPT). MPT measures the Brownian motion of fluorescent probe particles embedded in a material and relates this motion to rheological properties. Using time-cure superposition (TCS), we characterize the microstructure of these networks at the gel-sol phase transition by calculating the critical relaxation exponent, n, for each network with different amounts of excess thiol. Based on the measured n values, networks formed with 0% and 50% excess thiol are tightly cross-linked and elastic in nature. While networks formed with 100% excess are similar to ideal, percolated networks, which have equal viscous and elastic components. MPT measurements during degradation of these networks also measure a non-monotonic increase in probe motility. We hypothesize that this is network rearrangement near the phase transition. We then measure macroscopic material properties including the equilibrium modulus and stress relaxation. We measure a trend in bulk network properties that agrees with the values of n. Elastic modulus and stress relaxation measurements show that networks with 50% excess thiol are more elastic compared to the other two networks. As the amount of excess thiol is increased from 0% to 50%, the networks become more elastic. Further increasing excess thiol to 100% reduces the elastically effective cross-links. We hypothesize that these properties are due to network non-idealities, resulting in networks with 50% excess thiol that are more elastic. This work characterizes dynamic rheological properties during degradation, which mimics processes that could occur during implantation. This work provides information that can be used in the future design of implantable materials enabling both the rheological properties and timescale of degradation to be specified.
Collapse
Affiliation(s)
- Shivani Desai
- Department of Chemical and Biomolecular Engineering, Lehigh University, 124 E Morton St, Bethlehem, PA, 18015, USA.
| | - Benjamin J Carberry
- Department of Chemical and Biological Engineering, University of Colorado at Boulder, Boulder, CO, 80309, USA
| | - Kristi S Anseth
- Department of Chemical and Biological Engineering, University of Colorado at Boulder, Boulder, CO, 80309, USA
| | - Kelly M Schultz
- Department of Chemical and Biomolecular Engineering, Lehigh University, 124 E Morton St, Bethlehem, PA, 18015, USA.
| |
Collapse
|
18
|
Sharma H, Anil K, Parekh S, Pujari P, Shewale S, Desai S, Madhusudhan R, Patel J, Eswaraiah A, Rao H, Gairola S, Shaligram U. A phase-I, open label clinical trial to assess the safety & tolerability of qHPV vaccine manufactured by Serum Institute of India Pvt. Ltd. in adults. Vaccine X 2023; 14:100313. [PMID: 37234594 PMCID: PMC10205786 DOI: 10.1016/j.jvacx.2023.100313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Revised: 05/05/2023] [Accepted: 05/06/2023] [Indexed: 05/28/2023] Open
Abstract
Background This first in human study was designed as an open label clinical trial to assess safety and tolerability of Serum Institute of India Pvt. Ltd. (SIIPL) quadrivalent HPV (qHPV) vaccine. Methods A total of 48 healthy male and female (24 each) adult volunteers were administered a 0.5 ml single dose of SIIPL qHPV vaccine intramuscularly, and were followed for one month for safety outcomes viz., immediate, solicited, unsolicited and serious adverse events. Results 47 subjects completed the study in compliance with protocol. One subject had pain immediately after immunization which was recovered without treatment. None of the participants experienced any other local or systemic solicited AEs and serious AE. Conclusion qHPV vaccine manufactured by SIIPL was found to be safe and well tolerable in adults. Further clinical development should continue to assess safety and immunogenicity, in the target population following recommended 2 and 3-dose schedule.Clinical Trial Registration - CTRI/2017/02/007785.
Collapse
Affiliation(s)
- Hitt Sharma
- Serum Institute of India Pvt. Ltd., Pune, India
| | - K. Anil
- Syngene International Limited, Bangalore, India
| | | | | | | | | | | | - Jaya Patel
- Syngene International Limited, Bangalore, India
| | | | - Harish Rao
- Serum Institute of India Pvt. Ltd., Pune, India
| | | | | |
Collapse
|
19
|
Sharma H, Marthak K, Parekh S, Pujari P, Shewale S, Desai S, Patel A, Rao H, Gairola S, Shaligram U. A Phase I study to evaluate safety and tolerability of DTaP-IPV + Hib vaccine in healthy adult volunteers in India. Vaccine X 2023; 14:100300. [PMID: 37128477 PMCID: PMC10148180 DOI: 10.1016/j.jvacx.2023.100300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 04/05/2023] [Accepted: 04/06/2023] [Indexed: 05/03/2023] Open
Abstract
Background To assess safety and tolerability of a diphtheria and tetanus toxoid, acellular pertussis, inactivated poliovirus and Haemophilus influenza type B conjugate adsorbed vaccine (DTaP-IPV + Hib), manufactured by Serum Institute of India Pvt. Ltd. (SIIPL)'s, the current first-in-human Phase 1 study was conducted in healthy adults. Methods Vaccine was administered as a single 0.5 mL dose intramuscularly into deltoid muscle of 24 healthy adults aged 18-45 years, who were then followed prospectively for one month for safety outcomes. Results All 24 participants completed the study in compliance with protocol. Four solicited adverse events were reported in three participants during the study; all adverse events were mild and recovered completely. No deaths, unsolicited adverse events, or serious adverse events were reported. Conclusion SIIPL DTaP-IPV + Hib vaccine was well tolerated and safe in study subjects. Further clinical development will be conducted to assess safety and immunogenicity in young children, the target population.Clinical Trial Registration: CTRI/2017/07/009034.
Collapse
Affiliation(s)
- Hitt Sharma
- Serum Institute of India Pvt. Ltd., Pune 411028, India
- Corresponding author at: Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India.
| | - Kiran Marthak
- Lambda Therapeutic Research Ltd., Ahmedabad 382481, India
| | - Sameer Parekh
- Serum Institute of India Pvt. Ltd., Pune 411028, India
| | - Pramod Pujari
- Serum Institute of India Pvt. Ltd., Pune 411028, India
| | - Sunil Shewale
- Serum Institute of India Pvt. Ltd., Pune 411028, India
| | - Shivani Desai
- Serum Institute of India Pvt. Ltd., Pune 411028, India
| | - Akash Patel
- Lambda Therapeutic Research Ltd., Ahmedabad 382481, India
| | - Harish Rao
- Serum Institute of India Pvt. Ltd., Pune 411028, India
| | - Sunil Gairola
- Serum Institute of India Pvt. Ltd., Pune 411028, India
| | | |
Collapse
|
20
|
Shelke G, Kad V, Pandiselvam R, Yenge G, Kakade S, Desai S, Kukde R, Singh P. Physical and functional stability of spray-dried jamun (Syzygium cumini L.) juice powder produced with different carrier agents. J Texture Stud 2023; 54:560-570. [PMID: 36883842 DOI: 10.1111/jtxs.12749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Revised: 01/26/2023] [Accepted: 03/03/2023] [Indexed: 03/09/2023]
Abstract
Jamun (Syzygium cumini L.) fruit is an underutilized source of bioactive phytochemicals. Therefore, preserving this fruit in various forms over the year is necessary. Spray drying can effectively preserve jamun juice; but the stickiness issue of fruit juice powder mainly arises during the drying, which may be overcome by using different carriers. Consequently, this experiment aimed to ascertain the effect of different carrier types (maltodextrin, gum arabic, whey protein concentrate, waxy starch, and maltodextrin: gum arabic) on the physical, flow, reconstitution, functional, and color stability of spray-dried jamun juice powder. The physical parameters of the produced powder such as moisture content, bulk, and tapped density were in the range of 2.57%-4.95% (w.b.), 0.29-0.50 and 0.45-0.63 g/mL, respectively. The powder yield ranged between 55.25% and 75.9%. The flow characteristics, Carr's index and Hausner ratio, were in the range of 20.89-35.90 and 1.26-1.56, respectively. Reconstitution attributes viz., wettability, solubility, hygroscopicity, and dispersibility were in the range of 90.3-199.7 s, 55.28%-95%, 15.23-25.86 g/100 g, and 70.97%-95.79%, respectively. The functional attributes include total anthocyanin, total phenol content, and encapsulation efficiency, were in the range of 75.13-110.01 mg/100 g, 129.48-215.02 g GAE/100 g, and 40.49%-74.07%, respectively. The L*, a*, and b* values ranged from 41.82 to 70.86, 14.33 to 23.04, -8.12 to -0.60, respectively. A combination of maltodextrin and gum arabic was found effective in producing jamun juice powder with appropriate physical, flow, functional, and color attributes.
Collapse
Affiliation(s)
- Ganesh Shelke
- Department of Agricultural Process Engineering, Dr. ASCAE&T Mahatma Phule Agricultural University, Rahuri, India
| | - Vikram Kad
- Department of Agricultural Process Engineering, Dr. ASCAE&T Mahatma Phule Agricultural University, Rahuri, India
| | - Ravi Pandiselvam
- Physiology, Biochemistry and Post-Harvest Technology Division, ICAR-Central Plantation Crops Research Institute, Kasaragod, 671124, India
| | - Govind Yenge
- Department of Agricultural Process Engineering, Dr. ASCAE&T Mahatma Phule Agricultural University, Rahuri, India
| | - Sudama Kakade
- Department of Agricultural Process Engineering, Dr. ASCAE&T Mahatma Phule Agricultural University, Rahuri, India
| | - Shivani Desai
- Department Food Engineering, National Institute of Food Technology Entrepreneurship and Management (NIFTEM), Sonipat, 131028, India
| | - Ritu Kukde
- Department of Agricultural Process Engineering, Dr. ASCAE&T Mahatma Phule Agricultural University, Rahuri, India
| | - Punit Singh
- Department of Mechanical Engineering, Institute of Engineering and Technology, GLA University, Mathura, 281406, India
| |
Collapse
|
21
|
Williams-Beecher C, Basrani B, Desai S, Cardoso EOC, Tenenbaum HC, Azarpazhooh A. A Retrospective Study on Endodontic Treatment Outcomes in Patients with Special Needs. J Endod 2023:S0099-2399(23)00241-8. [PMID: 37164169 DOI: 10.1016/j.joen.2023.04.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2021] [Revised: 04/26/2023] [Accepted: 04/27/2023] [Indexed: 05/12/2023]
Abstract
INTRODUCTION Outcomes of endodontic treatment in patients with special needs are not fully understood, leading to reluctance in performing endodontic treatment. METHODS This retrospective cohort study evaluated the periapical healing and tooth survival in patients with special needs who had permanent teeth endodontically treated in a hospital setting between 1998 to 2019. Data characterization was performed using univariate analyses. Logistic and Cox regression analyses (P<0.05) were performed to identify the odds ratio (OR) and hazard ratio (HR) of the potential prognostic factors, respectively. These predictors were chosen from previous outcome studies in the general population and patients with special needs. RESULTS 61 patients (108 teeth) met the inclusion criteria. Most common treatment modality was initial therapy with 81.5% of cases being managed without a need for general anesthesia. Healing rate for initial endodontic treatment was 89.9% and was affected by no restoration at follow-up (OR=0.15, 95%CI:0.12, 0.71, P=0.02). After a mean follow up of 79.36±59.6 months, the survival rate was 73% and was correlated with gender (HR for males = 0.3; 95% CI, 0.1-0.6; P <0.05) and age (HR for patients >45 years = 3.7; 95% CI, 1.7-8.2; P<0.05). The most common reason for tooth extraction was unrestorable tooth fracture. CONCLUSIONS Endodontic therapy without a need for general anesthesia is a viable treatment option for patients with special needs. If the overall patient condition permits, then treatment can be administered by community dentists rather than waiting for a patient to be seen in a hospital setting.
Collapse
Affiliation(s)
| | - B Basrani
- Faculty of Dentistry, University of Toronto, Toronto, ON, Canada
| | - S Desai
- Faculty of Dentistry, University of Toronto, Toronto, ON, Canada; Centre for Advanced Dental Research and Care, Mount Sinai Hospital, Toronto, ON, Canada
| | - E O C Cardoso
- Faculty of Dentistry, University of Toronto, Toronto, ON, Canada; Centre for Advanced Dental Research and Care, Mount Sinai Hospital, Toronto, ON, Canada
| | - H C Tenenbaum
- Faculty of Dentistry, University of Toronto, Toronto, ON, Canada; Centre for Advanced Dental Research and Care, Mount Sinai Hospital, Toronto, ON, Canada
| | - A Azarpazhooh
- Faculty of Dentistry, University of Toronto, Toronto, ON, Canada; Centre for Advanced Dental Research and Care, Mount Sinai Hospital, Toronto, ON, Canada; Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
| |
Collapse
|
22
|
Desai S, Jarmi T, Ruiz J, Paghdar S, Patel P, Malkani S, Nativi J, Yip D, Lyle M, Leoni J, Goswami R. Renal Function Stabilization in Patients with Advanced Heart Failure and Chronic Kidney Disease Supported with Impella 5.5 as a Bridge to Transplantation. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
23
|
Cochrane A, Nable M, Barber A, Shah P, Kennedy J, Isseh I, Rollins A, Thatcher A, Bussa K, Mauro K, Maydosz M, Sinha S, Desai S, Psotka M. An Overlooked Contributor to CAV. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
24
|
Ruiz J, Desai S, Paghdar S, Malkani S, Nativi J, Yip D, Patel P, Leoni J, Lyle M, Goswami R. The Impact of Axillary Mechanical Circulatory Support in Patients Awaiting Heart Transplantation with Pulmonary Hypertension. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
25
|
Desai S, Soto-Arenall M, Ruiz J, Postell A, Paghdar S, Malkani S, Nativi J, Patel P, Yip D, Lyle M, Leoni J, Goswami R. Systemic Effects of Impella 5.5 Purge Solution in Patients with Heart Failure Cardiogenic Shock. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
26
|
Goswami R, Jang J, Ruiz J, Desai S, Paghdar S, Malkani S, Yip D, Leoni J, Patel P, Lyle M, Nativi J. Artificial Intelligence to Predict Death or Transplant in ATTR Amyloidosis Cardiomyopathy. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
27
|
Desai S, Ruiz J, Paghdar S, Malkani S, Nativi J, Juan L, Yip D, Patel P, Lyle M, Goswami R. Cardiogenic Shock in Eosinophilic Myocarditis. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
28
|
Patel K, Yadalam A, DeStefano R, Almuwaqqat Z, Desai S, Alkhoder A, Ejaz K, Alvi Z, Book W, Gupta D, Quyyumi A. Lipoprotein(a) Levels Predict Development of Cardiac Allograft Vasculopathy. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
29
|
Nable M, Kumar S, Goldberg J, Cochrane A, Psotka M, Tang D, Isseh I, Desai S, Rollins A, Klein K, Bussa K, Mauro K, Maydosz M, Thatcher A, Kennedy J, Shah P. Does Echocardiography-Guided Endomyocardial Biopsy Reduce the Incidence of Tricuspid Regurgitation after Heart Transplantation. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
30
|
Jang J, Ruiz J, Desai S, Sareyyupoglu B, Paghdar S, Malkani S, Landolfo K, Patel P, Nativi J, Yip D, Lyle M, Leoni J, Pham S, Goswami R. Mid-Term Survival in Patients with Advanced Heart Failure Receiving an Impella Device Intended as Bridge to Transplantation. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
31
|
Kamble P, Desai S, Bhonde R, Sanap A, Shimpi J, Kumbhar R, Kokani M, Kharat A. Therapeutic Potential of Metformin-preconditioned Mesenchymal Stem Cells for Pancreatic Regeneration. Curr Drug Discov Technol 2023:CDDT-EPUB-130070. [PMID: 36892116 DOI: 10.2174/1570163820666230309094233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2022] [Revised: 10/15/2022] [Accepted: 01/11/2023] [Indexed: 03/10/2023]
Abstract
BACKGROUND Diabetes occurs due to insulin deficiency or less insulin. To manage this condition, insulin administration as well as increased insulin sensitivity is required, but exogeneous insulin cannot replace the sensitive and gentle regulation of blood glucose levels same as β cells of healthy individuals. By considering the ability of regeneration and differentiation of stem cells, the current study planned to evaluate the effect of metformin preconditioned buccal fat pad (BFP) derived mesenchymal stem cells (MSCs) on streptozotocin (STZ) induced diabetes mellitus in Wistar rats. MATERIALS & METHODS The disease condition was established by using a diabetes-inducing agent STZ in Wistar rats. Then, the animals were grouped into disease control, blank, and test groups. Only the test group received the metformin-preconditioned cells. The total study period for this experiment was 33 days. During this period, the animals were monitored for blood glucose level, body weight, and food-water intake twice a week. At the end of 33 days, the biochemical estimations for serum insulin level and pancreatic insulin level were performed. Also, histopathology of the pancreas, liver and skeletal muscle was performed. RESULTS The test groups showed a decline in the blood glucose level and an increase in the serum pancreatic insulin level as compared to the disease group. No significant change in food and water intake was observed within the three groups, while body weight was significantly reduced in the test group when compared with the blank group, but the life span was increased when compared with the disease group. CONCLUSION In the present study, we concluded that metformin preconditioned buccal fat pad-derived mesenchymal stem cells have the ability to regenerate damaged pancreatic β cells and have antidiabetic activity, and this therapy is a better choice for future research.
Collapse
Affiliation(s)
- Prajakta Kamble
- Department of Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune
| | - Shivani Desai
- Department of Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune
| | - Ramesh Bhonde
- Director Research, Dr. D. Y. Patil Vidyapeeth, Pimpri, Pune
| | - Avinash Sanap
- Regenerative Medicine Laboratory, Dr. D. Y. Patil Dental College and Hospital, Pimpri, Pune
| | - Jagruti Shimpi
- Department of Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune
| | - Rohit Kumbhar
- Department of Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune
| | - Manesh Kokani
- Department of Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune
| | - Avinash Kharat
- Regenerative Medicine Laboratory, Dr. D. Y. Patil Dental College and Hospital, Pimpri, Pune
| |
Collapse
|
32
|
Desai A, Anavim A, Perez I, Yun J, Desai S, Li S, Khanna V. Abstract No. 592 Incidence of Caval Extension of Iliofemoral DVT in Patients Undergoing Thrombectomy. J Vasc Interv Radiol 2023. [DOI: 10.1016/j.jvir.2022.12.450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023] Open
|
33
|
Desai A, Perez I, Anavim A, Yun J, Desai S, Li S, Natarajan B, Brady P. Abstract No. 591 Transvenous Endovascular Tricuspid Vegectomy Using Large Bore Aspiration with Real Time Transesophageal ECHO: A Minimally Invasive Alternative to Open Vegectomy. J Vasc Interv Radiol 2023. [DOI: 10.1016/j.jvir.2022.12.449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023] Open
|
34
|
Singh S, Sharanagat VS, Desai S, Kumar K, Upadhyay S, Chakraborty G. Interaction of Pulsed Electric Modified Elephant Foot Yam (
Amorphophalluspaeoniifolius
) Starch and Polyvinyl Alcohol to Enhance the Mechanical and Barrier Properties of Film. STARCH-STARKE 2023. [DOI: 10.1002/star.202200229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Affiliation(s)
- Shubham Singh
- Department of Food Engineering NIFTEM Kundli Haryana 131028 India
| | | | - Shivani Desai
- Department of Food Engineering NIFTEM Kundli Haryana 131028 India
| | - Kshitiz Kumar
- Department of Food Processing Technology A. D. Patel Institute of Technology New VallabhVidynagar Gujarat India
| | - Srishti Upadhyay
- Department of Food Engineering NIFTEM Kundli Haryana 131028 India
| | | |
Collapse
|
35
|
Quist-Nelson J, Desai S, Reilly K, Keil A, Bruce K, Swanson M, Cobb B, Zahn K, McKenzie C, Coviello E, Mallampati D, Kolarczyk L. Increasing postpartum hemorrhage checklist use: a quality improvement initiative. Am J Obstet Gynecol 2023. [DOI: 10.1016/j.ajog.2022.11.855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
36
|
Phadtare P, Patil D, Desai S. Nanotechnology: Newer Approach in Insulin Therapy. Pharm Nanotechnol 2023; 11:3-9. [PMID: 36173054 DOI: 10.2174/2211738510666220928111142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2022] [Revised: 08/24/2022] [Accepted: 08/30/2022] [Indexed: 11/22/2022]
Abstract
Insulin is a peptide hormone released by pancreatic beta cells. An autoimmune reaction in diabetes mellitus type 1 causes the beta cells to die, preventing insulin from being produced or released into the bloodstream; that impacts 30 million people globally and is linked to shortened lifespan due to acute and chronic repercussions. Insulin therapy aims to replicate normal pancreatic insulin secretion, which includes low levels of insulin that are always present to support basic metabolism, as well as the two-phase secretion of additional insulin in response to high blood sugar - an initial spike in secreted insulin, followed by an extended period of continued insulin secretion. This is performed by combining various insulin formulations at varying rates and lengths of time. Since the beginning of human insulin use, several advances in insulin formulations have been made to help meet these aims as much as possible, resulting in improved glycaemic control while limiting hypoglycemia. In this review, we looked at devices used by patients with type 1 diabetes, such as insulin pumps, continuous glucose monitors, and, more recently, systems that combine a pump with a monitor for algorithm-driven insulin administration automation. We intend to provide insight into supplementary therapies and nanotechnology employed in insulin therapy as a result of our review.
Collapse
Affiliation(s)
- Pallavi Phadtare
- Department of Pharmacology, Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, India
| | - Devendra Patil
- Department of Pharmacology, Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, India
| | - Shivani Desai
- Department of Pharmacology, Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, India
| |
Collapse
|
37
|
Sharma HJ, Parekh S, Pujari P, Shewale S, Desai S, Kawade A, Ravi M, Oswal J, James S, Mahantashetti N, Munshi R, Ghosh A, Rao V, Balsubramaniam S, Varughese P, Somshekhar A, Ginsburg AS, Rao H, Gautam M, Gairola S, Shaligram U. Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children in India. Expert Rev Vaccines 2023; 22:278-287. [PMID: 36883291 DOI: 10.1080/14760584.2023.2188942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/09/2023]
Abstract
BACKGROUND This study assessed safety and immunogenicity of Serum Institute of India Pvt Ltd (SIIPL)'s tetanus toxoid (TT), diphtheria toxoid (DT), and acellular pertussis booster vaccine (Tdap). RESEARCH DESIGN AND METHODS In this Phase II/III, multicenter, randomized, active-controlled, open-label study, 1500 healthy individuals, aged 4-65 years, were randomized to receive a single dose of SIIPL Tdap or comparator Tdap vaccine (Boostrix®; GlaxoSmithKlines, India). Adverse events (AEs) during initial 30 minutes, 7-day, 30-day post-vaccination were assessed. Blood samples were taken before and 30 days post-vaccination for immunogenicity assessment. RESULTS No significant differences in incidence of local and systemic solicited AEs were observed between the two groups; no vaccine-related serious AEs were reported. SIIPL Tdap was non-inferior to comparator Tdap in achieving booster responses to TT and DT in 75.2% and 70.8% of the participants, respectively, and to pertussis toxoid (PT), pertactin (PRN), and filamentous hemagglutinin (FHA) in 94.3%, 92.6%, and 95.0% of the participants, respectively. Anti-PT, anti-PRN, and anti-FHA antibody geometric mean titers in both the groups, were significantly higher post-vaccination compared to pre-vaccination. CONCLUSIONS Booster vaccination with SIIPL Tdap was non-inferior to comparator Tdap with respect to immunogenicity against tetanus, diphtheria, and pertussis and was well tolerated.
Collapse
Affiliation(s)
- Hitt J Sharma
- Department of Clinical Research and Pharmacovigilance, Serum Institute of India Pvt. Ltd, Pune, India
| | - Sameer Parekh
- Department of Clinical Research and Pharmacovigilance, Serum Institute of India Pvt. Ltd, Pune, India
| | - Pramod Pujari
- Department of Clinical Research and Pharmacovigilance, Serum Institute of India Pvt. Ltd, Pune, India
| | - Sunil Shewale
- Department of Clinical Research and Pharmacovigilance, Serum Institute of India Pvt. Ltd, Pune, India
| | - Shivani Desai
- Department of Clinical Research and Pharmacovigilance, Serum Institute of India Pvt. Ltd, Pune, India
| | - Anand Kawade
- Department of Pediatrics, KEM Hospital Research Centre, Vadu Rural Health Program, Pune, India
| | - Mandyam Ravi
- Department of Pediatrics, JSS Hospital, Mysore, India
| | - Jitendra Oswal
- Department of Pediatrics, Bharti Vidyapeeth Deemed University Medical College and Hospital, Pune, India
| | - Saji James
- Department of Pediatrics, Sri Ramchandra Institute of Higher Education and Research, Chennai, India
| | - N Mahantashetti
- Department of Pediatrics, KLE's Dr. Prabhakar Kore Hospital, Belgavi, India
| | - Renuka Munshi
- Department of Clinical Pharmacology, Topiwala National Medical College and Bai Yamunabai Laxman Nair Charitable Hospital, Mumbai, India
| | - Apurba Ghosh
- Department of Pediatrics, Institute of Child Health, Kolkata, India
| | - Venkateshwar Rao
- Department of Medicine, Global Gleneagles Hospitals, Hyderabad, India
| | | | - P Varughese
- Department of Pediatrics, Christian Medical College, Ludhiana, India
| | - A Somshekhar
- Department of Pediatrics, M. S. Ramaiah Medical College & Hos, Bengaluru, India
| | | | - Harish Rao
- Production Department, Serum Institute of India Pvt Ltd, Pune, India
| | - Manish Gautam
- Department of Quality Control, Serum Institute of India Pvt Ltd, Pune, India
| | - Sunil Gairola
- Department of Quality Control, Serum Institute of India Pvt Ltd, Pune, India
| | - Umesh Shaligram
- Production Department, Serum Institute of India Pvt Ltd, Pune, India
| |
Collapse
|
38
|
Kumbhar RG, Desai S, Bhonde RR. Managing Type 1 Diabetes from Gynecological Waste: Trash to Treasure. Curr Diabetes Rev 2023; 19:1-4. [PMID: 35410613 DOI: 10.2174/1573399818666220411122832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Revised: 12/20/2021] [Accepted: 01/31/2022] [Indexed: 11/22/2022]
Abstract
Type 1 diabetes mellitus (T1DM), an autoimmune disease, involves the destruction of pancreatic β cells. β cells maintain glucose homeostasis by identifying blood glucose and accordingly releasing insulin to maintain normal physiologic glucose levels. Human umbilical cord blood (hUCB) cells pose a lesser risk of viral contamination due to low placental transmission during prenatal life. Additionally, they have advantages such as non-invasive harvest procedure gynecological waste, low immunogenicity, easy expansion in-vitro, and easy ethical access compared to deriving stem cells from other sources. According to the published preclinical data, the infusion of autologous cord blood cells is considered safe as they are non-antigenic. Depending on the degree of differentiation, the ability to regenerate themselves and the origin of many stem cell types can be differentiated. The application of stem cells (SCs) has great potential for managing T1DM due to their regenerative capabilities and promising immunological characteristics. Due to lesser ethical complications and easy procedures of isolation, hUCB has become a precious medical intervention.
Collapse
Affiliation(s)
- Rohit G Kumbhar
- Department of Pharmacology, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, India
| | - Shivani Desai
- Department of Pharmacology, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, India
| | - Ramesh R Bhonde
- Department of Research, Dr. D.Y. Patil Vidyapeeth, Pimpri, Pune, India
| |
Collapse
|
39
|
Staras SA, Bylund CL, Desai S, Harle CA, Richardson E, Khalil GE, Thompson LA. A novel method for evaluating physician communication: A pilot study testing the feasibility of parent-assisted audio recordings via Zoom. PEC Innov 2022; 1:100020. [PMID: 36212508 PMCID: PMC9534382 DOI: 10.1016/j.pecinn.2022.100020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Revised: 11/22/2021] [Accepted: 01/26/2022] [Indexed: 06/16/2023]
Abstract
OBJECTIVE Quality of physician consultations are best assessed via direct observation, but require intensive in-clinic research staffing. To evaluate physician consultation quality remotely, we pilot tested the feasibility of parents using their personal mobile phones to facilitate audio recordings of pediatric visits. METHODS Across four academic pediatric primary care clinics, we invited all physicians with a patient panel (n=20). For participating physicians, we identified scheduled patients from medical records. We invited parents to participate via text message and phone calls. During their adolescent's appointment, parents used their mobile phone to connect to Zoom for remote research staff to audio record. RESULTS In Spring 2021, five of 20 (25%) physicians participated. During a nine-week period, we invited parents of all 54 patients seen by participating physicians of which 15 (28%) completed adult consent and adolescent assent and 10 (19%) participated. For 9 recordings, at least 45% of the conversation was audible. CONCLUSIONS It was feasible and acceptable to directly observe physician consultations virtually with Zoom, although participation rates and potentially audio quality were lower. INNOVATION Patients used their cellular phone calling features to connect to Zoom where research staff audio-recorded their physician consultation to evaluate communication quality.
Collapse
Affiliation(s)
- Stephanie A.S. Staras
- Department of Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, USA
- Institute for Child Health Policy, University of Florida, Gainesville, USA
| | - Carma L. Bylund
- Department of Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, USA
- Institute for Child Health Policy, University of Florida, Gainesville, USA
| | - Shivani Desai
- Department of Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, USA
| | - Christopher A. Harle
- Department of Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, USA
| | - Eric Richardson
- Department of Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, USA
| | - Georges E. Khalil
- Department of Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, USA
| | - Lindsay A. Thompson
- Department of Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, USA
- Institute for Child Health Policy, University of Florida, Gainesville, USA
- Department of Pediatrics, College of Medicine, University of Florida, Gainesville, USA
| |
Collapse
|
40
|
Cordoza M, Dinges D, Asch D, Shea J, Bellini L, Malone S, Desai S, Volpp K, Mott C, Coats S, Mollicone D, Basner M. Changes in Alertness Over Consecutive Workdays for Internal Medicine Interns: A Secondary Analysis of the iCOMPARE Trial. Sleep Med 2022. [DOI: 10.1016/j.sleep.2022.05.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
41
|
Desai S, Desai S. The Building of a Cancer Center for the Rural Folk. Indian J Surg Oncol 2022; 13:104-105. [PMID: 36691495 PMCID: PMC9859942 DOI: 10.1007/s13193-022-01555-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Accepted: 05/13/2022] [Indexed: 01/25/2023] Open
Abstract
The requirement of rural folk differs from the requirements of the well-off urbanites. In developing nations, the onus of their healthcare falls upon the doctors practicing in the periphery. Since public awareness and support are minimal, income has to be generated from the poor folk. Hard work and simple living by the caretakers are the cornerstones to divert all profits for further growth of the hospital. Cancer therapy does not always require big investments. Scientific healthcare can be provided to the poor by doctors with good knowledge, hard work, and good skills.
Collapse
Affiliation(s)
- Sharad Desai
- Department of Surgical Oncology, Mahatma Gandhi Cancer Hospital, Miraj -416410, Dt Sangli, Maharashtra, India
| | - Shivani Desai
- Department of Head and Neck Oncology, Mahatma Gandhi Cancer Hospital, Miraj, India
| |
Collapse
|
42
|
Desai S, Kashalikar P, Sanap A, Shekatkar M, Bhonde R. Narrative Review of Anti-CD3 Antibody and Anti-CD20 Antibody:
Immunotherapeutic Strategies to Treat and Prevent Type 1 Diabetes. RAIAD 2022:RAIAD-EPUB-127735. [PMID: 36415095 DOI: 10.2174/2772270817666221122103029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 10/05/2022] [Accepted: 10/05/2022] [Indexed: 11/24/2022]
Abstract
Background and Objective:
Type 1 diabetes mellitus is a complex disease defined by
the loss of pancreatic cells, which leads to complete insulin insufficiency. The Diabetes Control
and Problems Trial defines the aims of Type 1 diabetes therapy as achieving adequate glycaemic
control, and preventing and avoiding recurrent bouts of hypoglycaemia. Despite ongoing efforts to
improve insulin therapy regimens, the actual hormone substitute therapy treats just the symptoms
of the disease, with no influence on disease pathology or etiopathogenesis. In recent decades, there
has been a lot of interest in preventative techniques in high-risk patients, based on the theory that
if a therapeutic intervention is adopted early in the disease, it can help maintain endogenous cell
function by protecting the remaining cell reservoir from autoimmune attack.
Methods:
Based on preclinical and clinical data, we have discussed some immunotherapeutic in
this meta-analysis. We referred to the preclinical and clinical studies for teplizumab and rituximab
from authentic databases and compiled the data. We used statistical analysis to do a meta-analysis.
Results:
In two immunotherapeutic anti-CD3 antibodies and anti-CD20 antibodies examples, teplizumab and rituximab, respectively, shows better efficacy as well as fewer side effects. We have
discussed this drug briefly based on their mechanism of action and meta-analysis, which compare
clinical efficacy.
Conclusion:
Immunotherapeutic can be a better option for preventing and protecting type one diabetes. Since, the existing literature does not have enough data to support any single drug concluding the same will not be appropriate. Hence further studies are required wherein different drugs
can be compared with similar sample sizes for each group of drugs.
Collapse
Affiliation(s)
- Shivani Desai
- Department of Pharmacology, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pune, India
| | - Prajakta Kashalikar
- Department of Pharmacology, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pune, India
| | - Avinash Sanap
- Regenerative Medicine Lab, Dr. D.Y. Patil Dental College and Hospital, Pune, India
| | - Madhura Shekatkar
- Regenerative Medicine Lab, Dr. D.Y. Patil Dental College and Hospital, Pune, India
| | | |
Collapse
|
43
|
Lawand PV, Desai S. Nanobiotechnology-Modified Cellular and Molecular Therapy as a Novel Approach for Autoimmune Diabetes Management. Pharm Nanotechnol 2022; 10:279-288. [PMID: 35927916 DOI: 10.2174/2211738510666220802111315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Revised: 04/26/2022] [Accepted: 05/09/2022] [Indexed: 06/15/2023]
Abstract
Several cellular and molecular therapies such as stem cell therapy, cell replacement therapy, gene modification therapy, and tolerance induction therapy have been researched to procure a permanent cure for Type 1 Diabetes. However, due to the induction of undesirable side effects, their clinical utility is questionable. These anti-diabetic therapies can be modified with nanotechnological tools for reducing adverse effects by selectively targeting genes and/or receptors involved directly or indirectly in diabetes pathogenesis, such as the glucagon-like peptide 1 receptor, epidermal growth factor receptor, human leukocyte antigen (HLA) gene, miRNA gene and hepatocyte growth factor (HGF) gene. This paper will review the utilities of nanotechnology in stem cell therapy, cell replacement therapy, beta-cell proliferation strategies, immune tolerance induction strategies, and gene therapy for type 1 diabetes management.
Collapse
Affiliation(s)
- Priyanka Vasant Lawand
- Department of Pharmacology, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, India
| | - Shivani Desai
- Department of Pharmacy Practice, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, India
| |
Collapse
|
44
|
Bajaj K, Vora D, Parab P, Shaikh H, Gulia S, Rath S, Bajpai J, Shet T, Desai S, Popat P, Rajan R, Nair N, Joshi S, Pathak R, Sarin R, Kembhavi Y, Rane S, Ghosh J, Badwe R, Gupta S. 23P Combination chemotherapy and hormone therapy (CHT) in patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC): A single-centre retrospective analysis. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
45
|
Desai S, Gebbia J, Kleiner G, Gans M. STAT1 GOF DISEASE PRESENTING WITH RECURRENT CUTANEOUS CELLULITIS AND UNREMARKABLE BASIC IMMUNOLOGY LABORATORY VALUES. Ann Allergy Asthma Immunol 2022. [DOI: 10.1016/j.anai.2022.08.913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
46
|
Staras SAS, Kastrinos AL, Wollney EN, Desai S, O'Neal LTJ, Johnson-Mallard V, Bylund CL. Differences in stakeholder-reported barriers and implementation strategies between counties with high, middle, and low HPV vaccine initiation rates: a mixed methods study. Implement Sci Commun 2022; 3:95. [PMID: 36068605 PMCID: PMC9450315 DOI: 10.1186/s43058-022-00341-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Accepted: 08/25/2022] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND A greater understanding of the county-level differences in human papillomavirus (HPV) vaccination rates could aid targeting of interventions to reduce HPV-related cancer disparities. METHODS We conducted a mixed-methods study to compare the stakeholder-reported barriers and efforts to increase HPV vaccination rates between counties within the highest, middle, and lowest HPV vaccine initiation (receipt of the first dose) rates among 22 northern Florida counties. Between August 2018 and April 2019, we recruited stakeholders (n = 68) through purposeful and snowball sampling to identify potential participants who were most knowledgeable about the HPV vaccination activities within their county and would represent a variety of viewpoints to create a diverse picture of each county, and completed semi-structured interviews. County-level HPV vaccine initiation rates for 2018 were estimated from the Florida Department of Health's immunization registry and population counts. Implementation strategies were categorized by level of importance and feasibility using the Expert Recommendations for Implementing Change (ERIC) taxonomy. We compared the barriers and implementation strategies for HPV vaccination between tercile groups of counties by HPV vaccine initiation rates: highest (18 stakeholders), middle (27 stakeholders), and lowest (23 stakeholders). RESULTS The majority of the 68 stakeholders were female (89.7%), non-Hispanic white (73.5%), and represented a variety of clinical and non-clinical occupations. The mentioned barriers represented five themes: healthcare access, clinician practices, community partnerships, targeted populations, and cultural barriers. Within themes, differences emerged between county terciles. Within healthcare access, the highest rate county stakeholders focused on transportation, lowest rate county stakeholders focused on lack of clinicians, and middle county stakeholders mentioned both. The number of ERIC quadrant I strategies, higher feasibility, and importance described decreased with the tercile for HPV vaccination: highest = 6, middle = 5, and lowest =3 strategies. CONCLUSIONS The differing barriers and strategies between the highest, middle, and lowest vaccination rate counties suggest that a tailored and targeted effort within the lowest and middle counties to adopt strategies of the highest rate counties may reduce disparities.
Collapse
Affiliation(s)
- Stephanie A S Staras
- Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, 2004 Mowry Road, Room 2238, Gainesville, FL, 32610, USA.
- The Institute for Child Health Policy, University of Florida, Gainesville, FL, USA.
| | - Amanda L Kastrinos
- Department of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Easton N Wollney
- Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, 2004 Mowry Road, Room 2238, Gainesville, FL, 32610, USA
| | - Shivani Desai
- Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, 2004 Mowry Road, Room 2238, Gainesville, FL, 32610, USA
| | - La Toya J O'Neal
- Department of Family, Youth, and Community Sciences, University of Florida, Gainesville, FL, USA
| | | | - Carma L Bylund
- Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, 2004 Mowry Road, Room 2238, Gainesville, FL, 32610, USA
| |
Collapse
|
47
|
Sheeka A, Singaravelou A, Bartlett E, Sivarasan N, Rawal B, Devaraj A, Desai S, Padley S, Ridge C. EP06.01-008 COVID-Protected Pathways for Image Guided Lunc Cancer Intervention During the COVID-19 Pandemic: A Cohort Study. J Thorac Oncol 2022. [PMCID: PMC9452024 DOI: 10.1016/j.jtho.2022.07.523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
48
|
Alexis A, Bhutani T, McMichael A, Choi O, Chan D, Rowland K, Gao L, Park-Wyllie L, Rodriguez A, Kindred C, Desai S. 694 Study design of a phase 3b, multicenter, randomized, double-blind, placebo-controlled trial of guselkumab (GUS) in patients with skin of color who have moderate to severe plaque and/or scalp psoriasis (VISIBLE). J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
49
|
Desai S, Desai A, Anavim A, Taghipour M, Khanna V, Natarajan B, Brady P. Abstract No. 230 Endovascular management approaches for hepatic artery stenosis following adult liver transplantation. J Vasc Interv Radiol 2022. [DOI: 10.1016/j.jvir.2022.03.311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
50
|
Bajpai J, Kashyap L, Vallathol D, Pathak R, Rath S, Sekar A, Mohanta S, Reddy A, Joshi S, Wadasadawala T, Nair N, Parmar V, Desai S, Shet T, Thakur M, Sarin R, Gupta S, Badwe R, Das A, Singh M. 100P Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|